Human T lymphoblastic leukemia/lymphoma cell strain and application thereof

A technology of lymphoma cells and blast cells, which is applied in the fields of biology and oncology, can solve problems such as constraints and failure to establish cell lines, and achieve the effect of shape stability

Active Publication Date: 2021-06-01
ZHEJIANG UNIV
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The research of ETP-ALL is also inseparable from cell lines, but at present, no ETP-ALL cell lines have been established from ETP-ALL

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Human T lymphoblastic leukemia/lymphoma cell strain and application thereof
  • Human T lymphoblastic leukemia/lymphoma cell strain and application thereof
  • Human T lymphoblastic leukemia/lymphoma cell strain and application thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1ZY

[0025] Example 1 ZYXY-T1 cell line preparation

[0026] Primary cell culture: Take 6ml of peripheral blood samples (male, male) obtained from the First Affiliated Hospital of Zhejiang University School of Medicine to separate leukemia mononuclear cells immediately. In a biosafety cabinet, take 6ml of peripheral blood samples dropwise into a 15ml sterile centrifuge tube pre-added with 6ml of lymphocyte separation medium, and centrifuge at 2000 rpm for 20 minutes. After centrifugation, take the mononuclear cell layer into a new 15ml sterile centrifuge tube, add 5ml sterile 1xPBS to resuspend the cells, and centrifuge at 2000 rpm for 5 minutes. After discarding the supernatant, add sterile erythrocyte lysate to lyse the cells at room temperature for 5 minutes, then centrifuge at 2000 rpm for 5 minutes. Discard the supernatant, add 5ml IMDM complete medium (IMDM 90% + fetal bovine serum 10%) to resuspend the cells, centrifuge at 1500 rpm for 5 minutes. Discard the supernatant, a...

example 2

[0029] Biological properties and application of example 2 human T lymphoblastic leukemia / lymphoma cell line

[0030] The invention adopts the IMDM medium containing 10% fetal bovine serum to cultivate the cell ZYXY-T1, so that it can grow stably in vitro and be passed down stably. Observed under the microscope, the cells are suspended single growth, round or oval. Wright-Giemsa staining showed that the cells were acute leukemia blasts with large and deeply stained nuclei. Flow cytometric analysis found that the cell line has the typical surface antigen characteristics of ETP-ALL, and it is the first ETP-ALL cell line established in the world. The cell line can be used for ETP-ALL pathogenesis research, screening and / or evaluation / preparation of tumor therapeutic drugs; development of tumor drug targets; preparation of tumor diagnostic products; screening of tumor biotherapeutic drugs / reagents; development and detection of tumor-related bioengineering products. details as fol...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a human T lymphoblastic leukemia/lymphoma cell strain as well as a construction method and an application thereof. The human T lymphoblastic leukemia/lymphoma cell strain is named as human T lymphoblastic leukemia/lymphoma ZYXY-T1, and is preserved in the China Center for Type Culture Collection (Wuhan University, Wuhan, China) on January 20, 2021, and the preservation number is CCTCC NO: C202143. According to the invention, mononuclear cells are extracted and separated from peripheral blood of a clinical human T lymphoblastic leukemia/lymphoma patient, and are subjected to in-vitro culture and continuous natural passage to obtain the T lymphoblastic leukemia/lymphoma protein. The leukemia cell strain has the typical surface antigen expression characteristic of ETP-ALL, namely, the leukemia cell strain does not express CD1alpha, CD5 and CD8, highly expresses a dry line marker CD34, has good in-vitro proliferation capacity and in-vivo tumorigenesis capacity, can be used as a cell material for researching the occurrence and development mechanism of ETP-ALL and individualized treatment in-vitro research, and can be used for in-vivo and in-vitro research of ETP-ALL drug screening, evaluation, and clinical medication.

Description

technical field [0001] The invention relates to the fields of biology and oncology, and relates to a human T-lymphoblastic leukemia / lymphoma cell line and its construction method and application Background technique [0002] Acute lymphoblastic leukemia (ALL) is a hematological malignancy of malignant clonal proliferation of immature lymphocytes, which is more common in children, and the incidence rate of adults is lower than that of children. ALL is divided into B-cell ALL (B-ALL) , accounting for about 85% of the number of patients, T-cell (T-ALL) accounts for about 15% of the number of patients. T-ALL is a high-risk type of ALL. Although combined chemotherapy can achieve a remission rate of 90% to 95%, nearly one-third of patients relapse, and the five-year overall survival rate is about 50%. For initial refractory and relapsed patients, the current treatment options are very limited, and the prognosis of patients is extremely poor. [0003] T-lymphoblastic leukemia / lym...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12N5/09C12Q1/02
CPCC12N5/0694G01N33/5011G01N33/5047C12N2503/02
Inventor 金洁李枫林王华锋主鸿鹄黄昕张仪胡超
Owner ZHEJIANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap